EurekAlert! reports that researchers at Seattle Children’s Research Institute are paving the way to use gene-edited B cells—a type of blood cell in the immune system—to treat a wide range of potential diseases that affect children with hemophilia and other protein deficiency disorders, autoimmune diseases and infectious diseases. If successful, the Seattle team’s research would open big doors for experimental cell therapy as the first-of-its-kind in clinical trials at Seattle Children’s in as soon as five years. Follow the link below to learn more.

Lead Research/Investigator

Dr. David Rawlings

Dr. Richard James

Source: EurekAlert!

Pin It on Pinterest